Neuren Pharmaceuticals Ltd (NEU)

Sydney
3.610
+0.080(+2.27%)
  • Volume:
    157,387
  • Bid/Ask:
    3.550/3.610
  • Day's Range:
    3.470 - 3.610

NEU Overview

Prev. Close
3.53
Day's Range
3.47-3.61
Revenue
80K
Open
3.53
52 wk Range
1.2-4.15
EPS
-0.11
Volume
157,387
Market Cap
454.74M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
493,112
P/E Ratio
-
Beta
2.44
1-Year Change
143.3%
Shares Outstanding
125,965,676
Next Earnings Date
21 Feb 2022
What is your sentiment on Neuren Pharmaceuticals Ltd?
or
Market is currently closed. Voting is open during market hours.

Neuren Pharmaceuticals Ltd Company Profile

Employees
0
Market
Australia

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The Company has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The Company is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. It is also planning a Phase II trial in Prader-Willi syndrome.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.